The unique profile of upregulated glycosylation in metastatic cancer cells may form the basis for the development of new biomarkers for the targeting and diagnosis of specific cancers. This study introduces a pancreatic cancer cell-derived exosome detection technology, which is based on the specific binding of lectins to distinctive glycan profiles on the surface of exosomes. Lectins with a high and specific affinity for sialic acid or fucose were attached to bifunctional Janus nanoparticles (JNPs), which facilitated interactions with pancreatic cancer cell-derived exosomes in a microfluidic device.
Here, we show that pancreatic cancer cell-derived exosomes from two cell lines and plasma samples collected from patients diagnosed with pancreatic cancer were successfully captured on the lectin-conjugated JNPs with affinities that were comparable to those of CA19-9, a conventional antibody. In addition, exosome detection using our platform could differentiate between metastatic and nonmetastatic pancreatic cancer cells. The lectin affinity to surface glycan of cancer cells can also be the strategy to target tumor with lectin-nanoparticles in photothermal therapy. This study opens the possibility to achieve a new early diagnosis marker and targeting moiety based on the glycan properties of pancreatic cancer cells.
Participation method details:
Please participate from the Zoom URL below.
Meeting ID: 849 9675 6149
※If you need credits as a special course in advanced pharmaceutical science, please register from here (Google Form).
★GTR international students only
This seminar is "GTR Lecture series on multidisciplinary problems (1pt)".
Enroll in gtr e-portfolio (Dead line: Dec.20)．Grades will be judged by report. Report submission is here by Jan.4.